Experience what's ahead

Approved for the treatment of excessive daytime sleepiness (EDS) in narcolepsy

XYREM at the 6 g and 9 g per night dosages significantly reduced median Epworth Sleepiness Scale (ESS) scores from baseline at week 8 compared to placebo1,2

Learn more

Approved for the treatment of cataplexy in narcolepsy

XYREM at the 6 g and 9 g per night dosages significantly decreased the median frequency of weekly cataplexy attacks from baseline at week 4 compared to placebo1

Learn more

The American Academy of Sleep Medicine (AASM) recommends sodium oxybate

As a standard of care for the treatment of:

  • Excessive daytime sleepiness in narcolepsy3
  • Cataplexy in narcolepsy3

XYREM CareConnect: Supporting your patients every step of the way

XYREM CareConnect offers access to information, resources and programs that can help support you and your patients on XYREM

Learn more

The XYREM® REMS Program: Designed with safety in mind

The goal of the XYREM REMS Program is to mitigate the risk of serious adverse outcomes resulting from inappropriate prescribing, misuse, abuse, and diversion of XYREM

Learn more

The process for prescribing XYREM® has changed:
the XYREM Success Program® is now the XYREM® REMS Program

Important changes to requirements and procedures need to be followed in order to prescribe XYREM and in order for patients to receive XYREM

LEARN MORE